Drug Trial Radar · NCT00448747
Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.
Last checked: Nov 20, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Jun 2007
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- AEterna ZentarisIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The diagnosis of growth hormone deficiency (GHD) in adults is established by laboratory testing in patients with an appropriate clinical history of hypothalamic pituitary disease. Two tests that are considered to be gold standard tests for the diagnosis of GHD are the insulin tolerance test (ITT) and growth hormone releasing hormone (GHRH) combined with L-arginine (L-ARG). However, these tests are either bothersome (given intravenously) to the patient or are linked with side effects. Therefore, an orally available compound like AEZS-130 (formerly ARD-07), if demonstrated to be safe and providing adequate sensitivity and specificity could be a welcome alternative and/or complement to the current available tests. The intent was to recruit 40 adult GHD (AGHD) patients and 40 healthy control subjects into this trial, but the original sponsor (Ardana Biosciences Ltd.) discontinued the study for financial reasons before this was completed. At the time of withdrawal of GHRH from the market in 2008, 42 AGHD patients and 10 normal controls had completed the study at 9 US sites. This study reactivated to complete the remaining 30 matched control subjects. Additionally upon agreement with the FDA in a Special Protocol Assessment (SPA), 10 additional adult growth hormone deficient and their matched control were planned to be enrolled into this trial for a total treated population of approximatively 100 subjects.
Conditions
- Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Interventions
AEZS-130 (formerly ARD-07)Drug
A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
L-ARG+GHRHDrug
A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
Primary outcomes
What the sponsor says the trial is designed to measure.
- Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) ConcentrationsTime frame: GH sampling: pre-dose and 30, 45, 60, 75, 90, 120, 150 min post-dose
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Cedars-Sinai Medical Center
Los Angeles, California
Harbor-UCLA Medical Center
Torrance, California
Northwestern University
Chicago, Illinois
Radiant Research Inc.
Chicago, Illinois
John Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Celerion
Lincoln, Nebraska
Celerion
Neptune City, New Jersey
Oregon Health & Science University
Portland, Oregon
Baylor College of Medicine
Houston, Texas
Cetero Research
San Antonio, Texas
VA Puget Sound HCS University of Washington
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.